- Home
- QNCX vs VTGN Comparison
QNCX vs VTGN Comparison
Compare QNCX & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- VTGN
- Stock Information
- Founded
- QNCX 2012
- VTGN 1998
- Country
- QNCX United States
- VTGN United States
- Employees
- QNCX N/A
- VTGN N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- VTGN Biotechnology: Pharmaceutical Preparations
- Sector
- QNCX Health Care
- VTGN Health Care
- Exchange
- QNCX Nasdaq
- VTGN Nasdaq
- Market Cap
- QNCX 85.9M
- VTGN 87.2M
- IPO Year
- QNCX 2019
- VTGN N/A
- Fundamental
- Price
- QNCX $1.61
- VTGN $2.90
- Analyst Decision
- QNCX Strong Buy
- VTGN
- Analyst Count
- QNCX 6
- VTGN 0
- Target Price
- QNCX $8.00
- VTGN N/A
- AVG Volume (30 Days)
- QNCX 137.7K
- VTGN 372.3K
- Earning Date
- QNCX 11-12-2025
- VTGN 11-06-2025
- Dividend Yield
- QNCX N/A
- VTGN N/A
- EPS Growth
- QNCX N/A
- VTGN N/A
- EPS
- QNCX N/A
- VTGN N/A
- Revenue
- QNCX N/A
- VTGN $646,000.00
- Revenue This Year
- QNCX N/A
- VTGN $10.19
- Revenue Next Year
- QNCX N/A
- VTGN $705.79
- P/E Ratio
- QNCX N/A
- VTGN N/A
- Revenue Growth
- QNCX N/A
- VTGN N/A
- 52 Week Low
- QNCX $0.69
- VTGN $1.90
- 52 Week High
- QNCX $2.45
- VTGN $3.88
- Technical
- Relative Strength Index (RSI)
- QNCX 49.14
- VTGN 39.33
- Support Level
- QNCX $1.56
- VTGN $2.84
- Resistance Level
- QNCX $1.65
- VTGN $3.64
- Average True Range (ATR)
- QNCX 0.07
- VTGN 0.21
- MACD
- QNCX 0.00
- VTGN -0.09
- Stochastic Oscillator
- QNCX 69.70
- VTGN 5.77
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.